在晚期肉瘤中测试低剂量普通化疗（脂质体多柔比星）联合抗癌药物 Peposertib
Peposertib (M3814) 和低剂量脂质体多柔比星 (Doxil®) 在转移性平滑肌肉瘤和其他软组织肉瘤患者中的 1 期研究
This phase I trial tests the safety, side effects, and best dose of combination therapy with liposomal doxorubicin and peposertib in treating patients with sarcoma that has spread from where it first started, to other places in the body (metastatic), or cannot be removed by surgery (unresectable) and for which no known cure is available (advanced). Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Liposomal doxorubicin is a form of the anticancer drug doxorubicin that is contained inside very tiny, fat-like particles. Liposomal doxorubicin may have fewer side effects and work better than other forms of the drug. Peposertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It may also enhance the activity of chemo- and radiotherapy. There is some pre-clinical evidence in animal models that combining peposertib with liposomal doxorubicin can shrink or stabilize certain types of cancer for longer than either drug alone, but it is not known if this will happen in people. Combination therapy with liposomal doxorubicin and peposertib may be effective in treating patients with advanced sarcoma.
研究概览
地位
条件
详细说明
PRIMARY OBJECTIVES:
I. To evaluate the safety and tolerability of peposertib in combination with low-dose pegylated liposomal doxorubicin hydrochloride (liposomal doxorubicin) as evaluated by the dose-limiting toxicity (DLT) rate at each tested dose level.
II. To determine the recommended phase 2 dose (RP2D) of liposomal doxorubicin and peposertib combination and determine the maximal tolerated dose (MTD) if identified.
SECONDARY OBJECTIVE:
I. To assess the pharmacokinetics of peposertib and liposomal doxorubicin used in combination with each other.
CORRELATIVE OBJECTIVES:
I. To test the hypothesis that soft tissue sarcomas (STS) with homologous recombination deficiency (HRD) like leiomyosarcomas (LMS) will be more susceptible to DNA-protein kinase inhibitor (PKi) in combination with low-dose liposomal doxorubicin.
II. To test the hypothesis that gammaH2AX and pNBS1 can be used as pharmacodynamic biomarkers of response to DNA-PKi in combination with low-dose liposomal doxorubicin.
III. To test the hypothesis that disease activity correlates with circulating tumor DNA levels in the plasma.
OUTLINE: This is a dose-escalation study of peposertib and liposomal doxorubicin.
Patients receive peposertib orally (PO) twice daily (BID) on days 1-28 of each cycle and liposomal doxorubicin intravenously (IV) on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression, unacceptable toxicity or withdrawal of consent. Patients undergo blood sample collection and computed tomography (CT) or magnetic resonance imaging (MRI) throughout the trial. Patients also undergo tissue biopsy and echocardiography (ECHO) or multigated acquisition scan (MUGA) during screening and on the trial.
Patients are followed for 30 days after removal from study or until death, whichever occurs first.
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
California
-
Los Angeles、California、美国、90033
- 招聘中
- USC / Norris Comprehensive Cancer Center
-
首席研究员：
- Mark Agulnik
-
接触：
- Site Public Contact
- 电话号码：323-865-0451
-
Los Angeles、California、美国、90033
- 招聘中
- Los Angeles General Medical Center
-
首席研究员：
- Mark Agulnik
-
接触：
- Site Public Contact
- 电话号码：323-865-0451
- 邮箱：uscnorrisinfo@med.usc.edu
-
-
Colorado
-
Aurora、Colorado、美国、80045
- 招聘中
- UCHealth University of Colorado Hospital
-
首席研究员：
- Breelyn A. Wilky
-
接触：
- Site Public Contact
- 电话号码：720-848-0650
-
-
Florida
-
Miami、Florida、美国、33136
- 招聘中
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
首席研究员：
- Emily E. Jonczak
-
接触：
- Site Public Contact
- 电话号码：305-243-2647
-
-
Illinois
-
Chicago、Illinois、美国、60637
- 招聘中
- University of Chicago Comprehensive Cancer Center
-
接触：
- Site Public Contact
- 电话号码：773-702-8222
- 邮箱：cancerclinicaltrials@bsd.uchicago.edu
-
首席研究员：
- Daniel J. Olson
-
New Lenox、Illinois、美国、60451
- 招聘中
- UC Comprehensive Cancer Center at Silver Cross
-
接触：
- Site Public Contact
- 电话号码：773-702-8222
- 邮箱：cancerclinicaltrials@bsd.uchicago.edu
-
首席研究员：
- Daniel J. Olson
-
Orland Park、Illinois、美国、60462
- 招聘中
- University of Chicago Medicine-Orland Park
-
接触：
- Site Public Contact
- 电话号码：773-702-8222
- 邮箱：cancerclinicaltrials@bsd.uchicago.edu
-
首席研究员：
- Daniel J. Olson
-
-
Maryland
-
Baltimore、Maryland、美国、21287
- 招聘中
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
接触：
- Site Public Contact
- 电话号码：410-955-8804
- 邮箱：jhcccro@jhmi.edu
-
首席研究员：
- H. Catherine Wilbur
-
Bethesda、Maryland、美国、20892
- 招聘中
- National Cancer Institute Developmental Therapeutics Clinic
-
接触：
- Site Public Contact
- 电话号码：800-411-1222
-
首席研究员：
- A P. Chen
-
-
Massachusetts
-
Boston、Massachusetts、美国、02215
- 招聘中
- Dana-Farber Cancer Institute
-
接触：
- Site Public Contact
- 电话号码：877-442-3324
-
首席研究员：
- Candace L. Haddox
-
-
Michigan
-
Ann Arbor、Michigan、美国、48109
- 暂停
- University of Michigan Rogel Cancer Center
-
-
Missouri
-
St Louis、Missouri、美国、63110
- 招聘中
- Washington University School of Medicine
-
首席研究员：
- Mia C. Weiss
-
接触：
- Site Public Contact
- 电话号码：800-600-3606
- 邮箱：info@siteman.wustl.edu
-
St Louis、Missouri、美国、63129
- 招聘中
- Siteman Cancer Center-South County
-
首席研究员：
- Mia C. Weiss
-
接触：
- Site Public Contact
- 电话号码：800-600-3606
- 邮箱：info@siteman.wustl.edu
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、美国、15232
- 招聘中
- UPMC Hillman Cancer Center
-
接触：
- Site Public Contact
- 电话号码：412-647-8073
-
首席研究员：
- Melissa A. Burgess
-
-
Texas
-
Houston、Texas、美国、77030
- 招聘中
- UT MD Anderson Cancer Center
-
接触：
- Site Public Contact
- 电话号码：866-632-6789
- 邮箱：askmdanderson@mdanderson.org
-
首席研究员：
- Michael S. Nakazawa
-
-
Virginia
-
Charlottesville、Virginia、美国、22908
- 招聘中
- University of Virginia Cancer Center
-
接触：
- Site Public Contact
- 电话号码：434-243-6303
- 邮箱：uvacancertrials@hscmail.mcc.virginia.edu
-
首席研究员：
- Paul V. Viscuse
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Patients must have histologically confirmed sarcoma that is metastatic or unresectable and for which there is no known curative treatment
-
Patients must have histologic diagnosis of leiomyosarcoma (LMS) or selected soft tissue sarcomas (myxofibrosarcoma [MFS], undifferentiated pleomorphic sarcoma [UPS], synovial sarcoma, or dedifferentiated liposarcoma [DDLPS]). Pathology review and confirmation of diagnosis will occur at the site enrolling the patient on this study. If the pathology has previously been reviewed by another site participating in the study, the diagnosis does not need to be re-reviewed at the enrolling site
-
Patients must have evaluable disease that is amenable to biopsy
-
Patients must have been treated with at least 1 prior line of therapy. Prior anthracycline use is permitted as long as the cumulative dose prior to enrollment does not exceed 360 mg/m^2
-
Age >= 18 years. Because no dosing or adverse event data are currently available on the use of peposertib (M3814) in combination with liposomal doxorubicin in patients < 18 years of age, children are excluded from this study
-
Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
-
Absolute neutrophil count >= 1,500/mcL
-
Platelets >= 100,000/mcL
-
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN)
-
Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional ULN
-
Hemoglobin >= 8 g/dL
-
Glomerular filtration rate (GFR) >= 51 mL/min/1.73 m^2 (per institutional estimate based on creatinine level)
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
-
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression and clinical symptoms are stable while off steroid support
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
-
Patients with known history of clinically significant cardiac disease, or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
-
Female patients of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
- Female patients of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 3 months after the last dose of peposertib (M3814) and 6 months after the last dose of liposomal doxorubicin
-
Male patients of reproductive potential must agree to avoid impregnating a partner while receiving study drug and for 3 months after the last dose of peposertib (M3814) and 6 months after the last dose of liposomal doxorubicin by complying with adequate methods of contraception
- Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the patient
-
Ability to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity (IDMC) who have a legally-authorized representative (LAR) and/or family member available will also be eligible
Exclusion Criteria:
-
Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia
-
Prior palliative radiotherapy within 14 days of cycle 1 day 1 and prior definitive radiotherapy within 42 days of cycle 1 day 1. Adverse effects of radiation therapy must resolve to baseline prior to cycle 1 day 1
-
Patients who are receiving any other investigational agents
-
History of allergic reactions attributed to compounds of similar chemical or biologic composition to peposertib (M3814) or other agents used in study
-
Patients who cannot discontinue concomitant medications or herbal supplements that are strong inhibitors or strong inducers of cytochrome P450 (CYP) isoenzymes CYP3A4/5, CYP2C9, and CYP2C19. Participants who cannot discontinue substrates with a narrow therapeutic index that are metabolized by CYP1A2, CYP2B6, CYP2C8, and CYP3A4/5 are ineligible. Patients may confer with the study doctor to determine if alternative medications can be used. The following categories of medications and herbal supplements must be discontinued for at least the specified period of time before the patient can be treated:
- Strong inducers of CYP3A4/5 and CYP2C19: >= 3 weeks prior to study treatment
- Strong inhibitors of CYP3A4/5 and CYP2C19: >= 1 week prior to study treatment
- Substrates of CYP3A4/5 with a narrow therapeutic index: >= 1 day prior to study treatment
- Strong inhibitors of CYP2C9: >= 1 week prior to study treatment
-
Patients who cannot discontinue concomitant proton-pump inhibitors (PPIs). Patients may confer with the study doctor to determine if such medications can be discontinued. These must be discontinued >= 5 days prior to study treatment. Patients do not need to discontinue calcium carbonate
-
Patients with left ventricular ejection fraction (LVEF) measurement below the institutional lower limit of normal (LLN) are excluded
-
Patients with uncontrolled intercurrent illness
-
Patients who cannot swallow tablets whole
-
Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are not eligible
-
Pregnant women are excluded from this study because peposertib (M3814) is an adenosine triphosphate (ATP)-competitive inhibitor of DNA-protein kinase catalytic subunit (PKcs) with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with peposertib (M3814), breastfeeding should be discontinued if the mother is treated with peposertib (M3814). These potential risks may also apply to other agents used in this study
-
Patients may not have received prior treatment with a DNA-protein kinase (PK) inhibitor
学习计划
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：不适用
- 介入模型：单组作业
- 屏蔽：无（打开标签）
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：Treatment (peposertib, liposomal doxorubicin)
Patients receive peposertib PO BID on days 1-28 of each cycle and liposomal doxorubicin IV on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression, unacceptable toxicity or withdrawal of consent. Patients undergo blood sample collection and CT or MRI throughout the trial. Patients also undergo tissue biopsy and ECHO or MUGA during screening and on the trial. |
Undergo blood sample collection
其他名称：
Undergo MRI
其他名称：
Undergo ECHO
其他名称：
Undergo MUGA
其他名称：
Undergo CT scan
其他名称：
Given IV
其他名称：
Undergo tissue biopsy
其他名称：
Given PO
其他名称：
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Dose limiting toxicity (DLT) rate
大体时间：Up to 28 days
|
The number and type of DLT seen at each dose level will be provided. The adverse events (AEs) will also be summarized by AE type and the maximum grade of the AE experienced by the patient for each dose level. DLT will be used to determine the recommended phase 2 dose of study drugs. |
Up to 28 days
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of adverse events
大体时间：Up to 30 days after the end of study treatment
|
AEs will be assessed using Common Terminology Criteria for Adverse Events version 5. |
Up to 30 days after the end of study treatment
|
|
Objective response rate
大体时间：Up to 28 days
|
Assessed with Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1. |
Up to 28 days
|
|
Progression free survival
大体时间：From study enrollment until disease progression (determined by RECIST v1.1) or death due to any cause, whichever occurs first
|
The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse. Patients who are alive at the time of analysis without a documented disease progression will be censored at the time of their last tumor evaluation. |
From study enrollment until disease progression (determined by RECIST v1.1) or death due to any cause, whichever occurs first
|
|
Homologous recombination deficiency (HRD) status
大体时间：Up to 1 year
|
Will be defined by HRD score and mutational signature analysis. |
Up to 1 year
|
|
Deoxyribonucleic acid damage repair activity
大体时间：Up to 1 year
|
Will be defined by gammaH2AX and NBS1 S343 phosphorylation based on the National Clinical Laboratory Network DDR3 assay. |
Up to 1 year
|
合作者和调查者
调查人员
- 首席研究员：Candace L Haddox、Dana-Farber - Harvard Cancer Center LAO
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- NCI-2023-00574
- UM1CA186709 (美国 NIH 拨款/合同)
- 10563 (其他标识符：CTEP)
- NCI-2023-00574 (注册表标识符：CTRP (Clinical Trial Reporting Program))
- 10563 (其他标识符：Dana-Farber - Harvard Cancer Center LAO)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)？
IPD 计划说明
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.